Swiss National Bank Sells 58,526 Shares of Qiagen NV (QGEN)

Swiss National Bank cut its holdings in Qiagen NV (NASDAQ:QGEN) by 5.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,017,738 shares of the company’s stock after selling 58,526 shares during the period. Swiss National Bank owned 0.45% of Qiagen worth $38,422,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Parallel Advisors LLC raised its position in Qiagen by 548.5% in the third quarter. Parallel Advisors LLC now owns 3,210 shares of the company’s stock worth $122,000 after acquiring an additional 2,715 shares during the period. First Bank & Trust raised its position in Qiagen by 156.0% in the second quarter. First Bank & Trust now owns 4,928 shares of the company’s stock worth $178,000 after acquiring an additional 3,003 shares during the period. Prudential Financial Inc. bought a new position in Qiagen in the third quarter worth approximately $206,000. Private Trust Co. NA bought a new position in Qiagen in the third quarter worth approximately $233,000. Finally, Lourd Capital LLC bought a new position in Qiagen in the third quarter worth approximately $250,000. Institutional investors and hedge funds own 62.23% of the company’s stock.

A number of analysts have recently issued reports on the stock. Zacks Investment Research reissued a “hold” rating on shares of Qiagen in a research note on Wednesday, November 14th. BidaskClub raised shares of Qiagen from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Morgan Stanley increased their price objective on shares of Qiagen from $39.00 to $41.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 31st. Commerzbank reissued a “buy” rating on shares of Qiagen in a research note on Tuesday, October 30th. Finally, Barclays reissued a “buy” rating on shares of Qiagen in a research note on Tuesday, October 30th. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $39.13.

QGEN opened at $34.51 on Friday. Qiagen NV has a fifty-two week low of $30.64 and a fifty-two week high of $39.45.

Qiagen (NASDAQ:QGEN) last posted its earnings results on Monday, October 29th. The company reported $0.35 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.02. The company had revenue of $377.90 million for the quarter, compared to analysts’ expectations of $380.11 million. The business’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.32 earnings per share.

TRADEMARK VIOLATION NOTICE: This story was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.wkrb13.com/2018/11/24/swiss-national-bank-sells-58526-shares-of-qiagen-nv-qgen.html.

Qiagen Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Recommended Story: What are the benefits of a balanced fund?

Institutional Ownership by Quarter for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply